Date: 2017-06-08
Type of information: Establishment of a new subsidiary in the EU
Compound: digital lab “BI X”
Company: Boehringer Ingelheim (Germany)
Therapeutic area: Technology - Services
Type agreement: establishment of a new subsidiary in the EU
Action mechanism:
Disease:
Details:
- • On June 8, 2017, Boehringer Ingelheim announced the founding of a new independent subsidiary BI X. With this new initiative, Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot.
- BI X will serve as a digital lab for its parent house. It will work closely together with all three business units of the company - Human Pharma, Animal Health and Biopharmaceuticals. The start-up will provide a platform for collaborating with specialists in the field of data science, agile software development and user experience design. It will develop prototypes for new products and solutions and test them together with the company’s business units in pilot phases. The business units will then use the successfully developed new products and solutions themselves and bring them to the market.
BI X will enter into operations in July 2017. Boehringer Ingelheim is set to invest €10 million in BI X in 2017 and has started to recruit globally a multidiscipline team of 50 specialists. The digital lab will be located in Ingelheim at the company’s headquarters in Germany.
Financial terms:
Latest news:
Is general: Yes
